Trial Profile
A Population-Based, Retrospective Cohort Study Assessing Treatment Toxicity in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)Treated with Abiraterone, Enzalutamide, Docetaxel, or Cabazitaxel
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Dec 2017
Price :
$35
*
At a glance
- Drugs Abiraterone (Primary) ; Cabazitaxel (Primary) ; Docetaxel (Primary) ; Enzalutamide (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- 27 Nov 2017 Results published in the Urology
- 16 May 2017 Results presented at the 112th Annual Meeting of the American Urological Association.
- 21 Mar 2017 New trial record